TY - JOUR
T1 - Highly compacted DNA nanoparticles with low MW PEG coatings
T2 - In vitro, ex vivo and in vivo evaluation
AU - Boylan, Nicholas J.
AU - Suk, Jung Soo
AU - Lai, Samuel K.
AU - Jelinek, Raz
AU - Boyle, Michael P.
AU - Cooper, Mark J.
AU - Hanes, Justin
N1 - Funding Information:
Funding was provided by the National Institutes of Health (NIH R01EB003558 and P01HL51811 ) and a postdoctoral fellowship from the Croucher Foundation to S.K.L. We thank Professor Alexander Klibanov (Department of Chemistry, the Massachusetts Institute of Technology) for providing the plasmid pd1GL3-RL. We also thank Meghan Ramsay and Sharon Watts at the Johns Hopkins Adult Cystic Fibrosis Center for cystic fibrosis sputum collection. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Biomedical Imaging and Bioengineering, the National Heart, Lung, and Blood Institute, or the National Institutes of Health.
PY - 2012/1/10
Y1 - 2012/1/10
N2 - Highly compacted DNA nanoparticles, composed of single molecules of plasmid DNA compacted with block copolymers of poly-l-lysine and 10 kDa polyethylene glycol (CK 30PEG 10k), mediate effective gene delivery to the brain, eyes and lungs in vivo. Nevertheless, we found that CK 30PEG 10k DNA nanoparticles are immobilized by mucoadhesive interactions in sputum that lines the lung airways of patients with cystic fibrosis (CF), which would presumably preclude the efficient delivery of cargo DNA to the underlying epithelium. We previously found that nanoparticles can rapidly penetrate human mucus secretions if they are densely coated with low MW PEG (2-5 kDa), whereas nanoparticles with 10 kDa PEG coatings were immobilized. We thus sought to reduce mucoadhesion of DNA nanoparticles by producing CK 30PEG DNA nanoparticles with low MW PEG coatings. We examined the morphology, colloidal stability, nuclease resistance, diffusion in human sputum and in vivo gene transfer of CK 30PEG DNA nanoparticles prepared using various PEG MWs. CK 30PEG 10k and CK 30PEG 5k formulations did not aggregate in saline, provided partial protection against DNase I digestion and exhibited the highest gene transfer to lung airways following inhalation in BALB/c mice. However, all DNA nanoparticle formulations were immobilized in freshly expectorated human CF sputum, likely due to inadequate PEG surface coverage.
AB - Highly compacted DNA nanoparticles, composed of single molecules of plasmid DNA compacted with block copolymers of poly-l-lysine and 10 kDa polyethylene glycol (CK 30PEG 10k), mediate effective gene delivery to the brain, eyes and lungs in vivo. Nevertheless, we found that CK 30PEG 10k DNA nanoparticles are immobilized by mucoadhesive interactions in sputum that lines the lung airways of patients with cystic fibrosis (CF), which would presumably preclude the efficient delivery of cargo DNA to the underlying epithelium. We previously found that nanoparticles can rapidly penetrate human mucus secretions if they are densely coated with low MW PEG (2-5 kDa), whereas nanoparticles with 10 kDa PEG coatings were immobilized. We thus sought to reduce mucoadhesion of DNA nanoparticles by producing CK 30PEG DNA nanoparticles with low MW PEG coatings. We examined the morphology, colloidal stability, nuclease resistance, diffusion in human sputum and in vivo gene transfer of CK 30PEG DNA nanoparticles prepared using various PEG MWs. CK 30PEG 10k and CK 30PEG 5k formulations did not aggregate in saline, provided partial protection against DNase I digestion and exhibited the highest gene transfer to lung airways following inhalation in BALB/c mice. However, all DNA nanoparticle formulations were immobilized in freshly expectorated human CF sputum, likely due to inadequate PEG surface coverage.
KW - Cystic fibrosis
KW - Gene therapy
KW - Mucus
KW - Sputum
UR - http://www.scopus.com/inward/record.url?scp=84855846254&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2011.08.031
DO - 10.1016/j.jconrel.2011.08.031
M3 - Article
AN - SCOPUS:84855846254
SN - 0168-3659
VL - 157
SP - 72
EP - 79
JO - Journal of Controlled Release
JF - Journal of Controlled Release
IS - 1
ER -